Home

The company has already identified and pre-screened a number of US clinical centres that have indicated strong interest to participate in the STAR-T trial. The company believes conditions for full IDE approval can be appropriately addressed within the 45-day timeframe outlined by the FDA, and once accepted, the company expects to provide additional detail on the trial.

David Cox, vice president of Global Regulatory of CytoSorbents stated: “We are pleased that the FDA has approved our randomised, controlled clinical trial for the removal of ticagrelor during cardiothoracic surgery to reduce perioperative bleeding complications. We will promptly address FDA’s conditions of approval and finalise the IDE protocol to best support a US marketing submission of our FDA Breakthrough Device technology for this application.”

Vincent Capponi, president and chief operating officer of CytoSorbents added: “We are very excited to have received the go ahead from the FDA to begin the STAR-T trial, that if successful, is expected to support our first US FDA marketing submission. In the future, we plan to leverage the alignment with FDA and the STAR-T study infrastructure, including the academic leadership, operational framework, and participating clinical trial sites to seek label expansions in antithrombotic removal beyond ticagrelor.“

In April 2020, the FDA granted CytoSorbents Breakthrough Device Designation to remove ticagrelor during cardiothoracic surgery, recognising this major unmet medical need. Each year, ticagrelor is prescribed to millions of cardiovascular patients worldwide to reduce the risk of recurrent hearts attack, stroke or cardiovascular death.

Ticagrelor is frequently preferred as first line therapy in patients presenting to hospitals with an acute coronary syndrome in preparation of percutaneous coronary intervention (PCI) and stent placement. However, up to 10% of these patients will require coronary artery bypass graft (CABG) open heart surgery and as several clinical studies, such as the PLATO trial, have shown, they face a very high risk of severe or life-threatening bleeding during surgery.

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua google bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua twitter bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua MySpace bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua LinkedIn bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua stumbleupon bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua icio bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua digg bài: CytoSorbents granted US FDA approval for STAR-T trial

Chia sẽ qua yahoo bài: CytoSorbents granted US FDA approval for STAR-T trial

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.